☆ 4.8 Meeting Abstract

Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc

CANCER RESEARCH (2015)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) plus /- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc

Rate this paper

Publish scientific posters with Peeref

Find the ideal target journal for your manuscript

Export Citation

Share Paper